{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:21:32Z","timestamp":1761920492878},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s15010-018-1214-5","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T01:19:05Z","timestamp":1537319945000},"page":"59-65","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab"],"prefix":"10.1007","volume":"47","author":[{"given":"Emanuela","family":"Zappulo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Ambra","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Di Grazia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alida","family":"Dominietto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Lamparelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gualandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Caligiuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Viscoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"key":"1214_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","volume":"100","author":"AS Lok","year":"1991","unstructured":"Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182\u20138.","journal-title":"Gastroenterology"},{"key":"1214_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0166-3542(01)00176-0","volume":"52","author":"I Chemin","year":"2001","unstructured":"Chemin I, Jeantet D, Kay A, Trepo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(\u2212) liver disease. Antivir Res. 2001;52:117\u201323.","journal-title":"Antivir Res"},{"key":"1214_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cld.458","volume":"5","author":"O Etzion","year":"2015","unstructured":"Etzion O, Ghany MG. Screening for hepatitis B virus to prevent viral reactivation\u2014who and when? Clin Liver Dis. 2015;5:47\u201350. \n                    https:\/\/doi.org\/10.1002\/cld.458\n                    \n                  .","journal-title":"Clin Liver Dis"},{"key":"1214_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"EASL","year":"2017","unstructured":"EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021\n                    \n                  .","journal-title":"J Hepatol"},{"key":"1214_CR5","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","volume":"16","author":"V Mallet","year":"2016","unstructured":"Mallet V, van Bommel F, Doerig C, Pischke S, Hermine O, Locasciulli A, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16:606\u201317. \n                    https:\/\/doi.org\/10.1016\/s1473-3099(16)00118-3\n                    \n                  .","journal-title":"Lancet Infect Dis"},{"key":"1214_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/bmt.2010.70","volume":"46","author":"M Vigano","year":"2011","unstructured":"Vigano M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011;46:125\u201331. \n                    https:\/\/doi.org\/10.1038\/bmt.2010.70\n                    \n                  .","journal-title":"Bone Marrow Transplant"},{"key":"1214_CR7","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bbmt.2009.05.001","volume":"15","author":"SP Hammond","year":"2009","unstructured":"Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2009;15:1049\u201359. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2009.05.001\n                    \n                  .","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"1214_CR8","doi-asserted-by":"publisher","first-page":"21455","DOI":"10.3390\/ijms151121455","volume":"15","author":"S Nakamoto","year":"2014","unstructured":"Nakamoto S, Kanda T, Nakaseko C, Sakaida E, Ohwada C, Takeuchi M, et al. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment. Int J Mol Sci. 2014;15:21455\u201367. \n                    https:\/\/doi.org\/10.3390\/ijms151121455\n                    \n                  .","journal-title":"Int J Mol Sci"},{"key":"1214_CR9","doi-asserted-by":"publisher","first-page":"O694","DOI":"10.1111\/1469-0691.12611","volume":"20","author":"M Mikulska","year":"2014","unstructured":"Mikulska M, Nicolini L, Signori A, Rivoli G, Del Bono V, Raiola AM, et al. Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2014;20:O694\u2013701. \n                    https:\/\/doi.org\/10.1111\/1469-0691.12611\n                    \n                  .","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"1214_CR10","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.bbmt.2011.04.006","volume":"17","author":"S Park","year":"2011","unstructured":"Park S, Kim K, Kim DH, Jang JH, Kim SJ, Kim WS, et al. Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2011;17:1630\u20137. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2011.04.006\n                    \n                  .","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"1214_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1365-2893.2006.00830.x","volume":"14","author":"A Knoll","year":"2007","unstructured":"Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat. 2007;14:478\u201383. \n                    https:\/\/doi.org\/10.1111\/j.1365-2893.2006.00830.x\n                    \n                  .","journal-title":"J Viral Hepat"},{"key":"1214_CR12","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","volume":"32","author":"WK Seto","year":"2014","unstructured":"Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32:3736\u201343. \n                    https:\/\/doi.org\/10.1200\/jco.2014.56.7081\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1214_CR13","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.cmi.2017.06.024","volume":"23","author":"G Gentile","year":"2017","unstructured":"Gentile G, Andreoni M, Antonelli G, Sarmati L. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. Clin Microbiol Infect. 2017;23:916\u201323.","journal-title":"Clin Microbiol Infect"},{"key":"1214_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215\u20139. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2014.10.039\n                    \n                  .","journal-title":"Gastroenterology"},{"key":"1214_CR15","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2014.15704","volume":"312","author":"H Huang","year":"2014","unstructured":"Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312:2521\u201330. \n                    https:\/\/doi.org\/10.1001\/jama.2014.15704\n                    \n                  .","journal-title":"JAMA"},{"key":"1214_CR16","doi-asserted-by":"publisher","first-page":"e0131545","DOI":"10.1371\/journal.pone.0131545","volume":"10","author":"W-C Chen","year":"2015","unstructured":"Chen W-C, Cheng J-S, Chiang P-H, Tsay F-W, Chan H-H, Chang H-W, et al. A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy. PloS One. 2015;10:e0131545.","journal-title":"PloS One"},{"key":"1214_CR17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.bbmt.2010.10.003","volume":"17","author":"S Coppoletta","year":"2011","unstructured":"Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, et al. Rituximab treatment for Epstein\u2013Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2011;17:901\u20137. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2010.10.003\n                    \n                  .","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"1214_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/bmt.2011.28","volume":"47","author":"A Dominietto","year":"2012","unstructured":"Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT, et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant. 2012;47:101\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"1214_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S1470-2045(08)70180-3","volume":"9","author":"F Frassoni","year":"2008","unstructured":"Frassoni F, Gualandi F, Podest\u00e0 M, Raiola AM, Ibatici A, Piaggio G, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I\/II study. Lancet Oncol. 2008;9:831\u20139.","journal-title":"Lancet Oncol"},{"key":"1214_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/bmt.2013.166","volume":"49","author":"A Raiola","year":"2014","unstructured":"Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2014;49:190.","journal-title":"Bone Marrow Transplant"},{"key":"1214_CR21","doi-asserted-by":"publisher","first-page":"946 e1","DOI":"10.1016\/j.cmi.2016.07.021","volume":"22","author":"C Cerva","year":"2016","unstructured":"Cerva C, Colagrossi L, Maffongelli G, Salpini R, Di Carlo D, Malagnino V, et al. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016;22:946 e1\u2013e8. \n                    https:\/\/doi.org\/10.1016\/j.cmi.2016.07.021\n                    \n                  .","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"1214_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.bbmt.2009.12.533","volume":"16","author":"L Giaccone","year":"2010","unstructured":"Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2010;16:809\u201317. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2009.12.533\n                    \n                  .","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"1214_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/hon.2195","volume":"34","author":"A Gupta","year":"2016","unstructured":"Gupta A, Punatar S, Gawande J, Bagal B, Mathew L, Bhat V, et al. Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation. Hematol Oncol. 2016;34:140\u20136. \n                    https:\/\/doi.org\/10.1002\/hon.2195\n                    \n                  .","journal-title":"Hematol Oncol"},{"key":"1214_CR24","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/jmv.20705","volume":"78","author":"SE Moses","year":"2006","unstructured":"Moses SE, Lim ZY, Sudhanva M, Devereux S, Ho AY, Pagliuca A, et al. Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol. 2006;78:1560\u20133. \n                    https:\/\/doi.org\/10.1002\/jmv.20705\n                    \n                  .","journal-title":"J Med Virol"},{"key":"1214_CR25","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1111\/liv.12882","volume":"35","author":"J-J Yoo","year":"2015","unstructured":"Yoo J-J, Cho EJ, Cho YY, Lee M, Lee DH, Cho Y, et al. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. Liver Int. 2015;35:2530\u20136. \n                    https:\/\/doi.org\/10.1111\/liv.12882\n                    \n                  .","journal-title":"Liver Int"},{"key":"1214_CR26","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/hep.510270628","volume":"27","author":"MI Allen","year":"1998","unstructured":"Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (Baltim, MD). 1998;27:1670\u20137. \n                    https:\/\/doi.org\/10.1002\/hep.510270628\n                    \n                  .","journal-title":"Hepatology (Baltim, MD)"},{"key":"1214_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1055\/s-2004-828676","volume":"24","author":"TL Wright","year":"2004","unstructured":"Wright TL. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis. 2004;24:31\u20136. \n                    https:\/\/doi.org\/10.1055\/s-2004-828676\n                    \n                  .","journal-title":"Semin Liver Dis"},{"key":"1214_CR28","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1016\/S1386-6532(05)80025-3","volume":"34","author":"YF Liaw","year":"2005","unstructured":"Liaw YF. The current management of HBV drug resistance. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2005;34:S143\u20136.","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"1214_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hep.21513","volume":"45","author":"AS Lok","year":"2007","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology (Baltim, MD). 2007;45:507\u201339. \n                    https:\/\/doi.org\/10.1002\/hep.21513\n                    \n                  .","journal-title":"Hepatology (Baltim, MD)"},{"key":"1214_CR30","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/JCO.2015.61.3745","volume":"33","author":"JP Hwang","year":"2015","unstructured":"Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol. 2015;33:2212\u201320. \n                    https:\/\/doi.org\/10.1200\/jco.2015.61.3745\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1214_CR31","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/liv.12097","volume":"33","author":"FW Chen","year":"2013","unstructured":"Chen FW, Coyle L, Jones BE, Pattullo V. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Int Off J Int Assoc Study Liver. 2013;33:1203\u201310. \n                    https:\/\/doi.org\/10.1111\/liv.12154\n                    \n                  .","journal-title":"Liver Int Off J Int Assoc Study Liver"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-018-1214-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-018-1214-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-018-1214-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T19:11:28Z","timestamp":1568833888000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-018-1214-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1007\/s15010-018-1214-5","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"assertion":[{"value":"7 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}